Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| 1 | 08-13-2025 | 06-30-2025 | 10-Q | |
| 2 | 05-14-2025 | 03-31-2025 | 10-Q | |
| 3 | 03-05-2025 | 01-01-1970 | 10-K | |
| 4 | 11-13-2024 | 09-30-2024 | 10-Q | |
| 5 | 08-13-2024 | 06-30-2024 | 10-Q |
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Canaccord Genuity analyst Kyle Mikson maintains GRAIL (NASDAQ:GRAL) with a Buy and raises the price target from $75 to $85.
The private placement included the participation by new and existing institutional investors, including Deep Track Capital, Far...
GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, and the Universit...
GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, and the Universit...
-SEC Filing
Samsung C&T and Samsung Electronics Will Make an Equity Investment of $110 Million Into GRAIL, Subject to Closing Condition...
